REQUEST A DEMO
Total
USD $0.00
Search more companies

Dar Al-Shifa Pharmaceuticals Plc (Palestine)

Main Activities: Medicinal and Botanical Manufacturing
Full name: Dar Al-Shifa Pharmaceuticals Plc Profile Updated: June 11, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

Pharmacare is a pharmaceutical company. The company specializes in the development, production, and marketing of generic and branded pharmaceuticals, including medications for infections, gastrointestinal, respiratory, cardiovascular, musculoskeletal, endocrine, and erectile dysfunction. They also offer veterinary medications and a dedicated oncology product range. Pharmacare has a presence in over 20 countries.

Legal Address
Beitunia,P.O Box 677
Ramallah and Al-Bireh; Gaza;

Contact Details: Purchase the Dar Al-Shifa Pharmaceuticals Plc report to view the information.

Website: http://www.pharmacare-ltd.net

Basic Information
Total Employees:
Purchase the Dar Al-Shifa Pharmaceuticals Plc report to view the information.
Outstanding Shares:
Purchase the Dar Al-Shifa Pharmaceuticals Plc report to view the information.
Financial Auditors:
Purchase the Dar Al-Shifa Pharmaceuticals Plc report to view the information.
Incorporation Date:
1986
Key Executives
Purchase this report to view the information.
Member of Sharia Board
Ownership Details
Purchase this report to view the information.
25.68%
Purchase this report to view the information.
20.51%
Purchase this report to view the information.
5.84%
Company Performance
Financial values in the chart are available after Dar Al-Shifa Pharmaceuticals Plc report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
33.38%
Total operating revenue
32.29%
Operating profit (EBIT)
121.95%
EBITDA
66.04%
Net Profit (Loss) for the Period
149.57%
Total assets
-5.79%
Total equity
-16.99%
Operating Profit Margin (ROS)
9.51%
Net Profit Margin
7.41%
Return on Equity (ROE)
11.97%
Debt to Equity Ratio
11.18%
Quick Ratio
0.08%
Cash Ratio
-0.06%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?